NEO News and Press, NeoGenomics Inc. From 03/31/23

2023-03-31 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET. The event will feature a prese...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize patient selection for clinical trials. Massive Bio, Inc., a private AI-enab...

2023-03-16 07:49:47 ET NeoGenomics ( NASDAQ: NEO ) said its RaDaR liquid biopsy test for molecular/minimal residual disease (MRD) was now commercially available. MRD refers to the very small number of cancer cells which may remain in the body during or after treatment...

FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR ® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). ...

2023-03-13 07:47:03 ET NeoGenomics ( NASDAQ: NEO ) said it launched multiple tests expanding its next-generation sequencing (NGS). The commercially available test now include, Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor ...

FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of...

Summary Improving top-line fundamentals, with upsides against consensus in core business segments. Moving core businesses into 2 separate divisions to focus on strategic initiatives in both. Profitability and return on capital are still a concern, so FY23 will be the key year to evi...

FT. MYERS, FL / ACCESSWIRE / February 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chris Smith, chief executive officer of NeoGenomics, and Jeff Sherman, chief financi...

The week was once again eventful in cryptocurrencies, but unlike last week it wasn't dominated by regulatory and political fights . A big announcement came from Coinbase (NASDAQ: COIN) , which built its own Layer 2 blockchain on Ethereum . There's no token for the blockchain,...